{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T14:12:30Z","timestamp":1762956750930,"version":"3.37.3"},"reference-count":23,"publisher":"The Journal of Rheumatology","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>We assessed coronavirus disease 2019 (COVID-19) vaccine uptake among individuals with immune-mediated inflammatory diseases (IMIDs) and the Ontario general population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We studied all residents aged \u2265 16 years who were alive and enrolled in the Ontario Health Insurance Plan as of December 14, 2020, when vaccination commenced (n = 12,435,914). Individuals with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), psoriasis (PsO), and inflammatory bowel disease (IBD) were identified using established disease-specific case definitions applied to health administrative data. Vaccination status was extracted from the provincial COVaxON registry. Weekly cumulative proportions of first and second doses up until October 3, 2021, were expressed as the vaccinated percentage of each disease group, compared to the general Ontario population, and stratified by age.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>By October 3, 2021, the cumulative percentage with at least 1 dose was 82.1% for the general population, 88.9% for those with RA, 87.4% for AS, 90.6% for PsA, 87.3% for PsO, and 87.0% for IBD. There was also a higher total cumulative percentage with 2 doses among IMIDs (83.8\u201388.2%) vs the general population (77.9%). The difference was also evident when stratifying by age. Individuals with IMIDs in the youngest age group initially had earlier uptake than the general population but remain the lowest age group with 2 doses (70.6% in the general population vs. 73.7\u201379.2% across IMID groups).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>While implementation of COVID-19 vaccination programs has differed globally, these Canadian estimates are the first to reassuringly show higher COVID-19 vaccine uptake among individuals with IMIDs.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.211148","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T13:20:15Z","timestamp":1642252815000},"page":"531-536","source":"Crossref","is-referenced-by-count":13,"title":["COVID-19 Vaccination Uptake Among Individuals With Immune-mediated Inflammatory Diseases in Ontario, Canada, Between December 2020 and October 2021: A Population-based Analysis"],"prefix":"10.3899","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7464-0460","authenticated-orcid":false,"given":"Jessica","family":"Widdifield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1473-1715","authenticated-orcid":false,"given":"Lihi","family":"Eder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-8543","authenticated-orcid":false,"given":"Simon","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7820-2046","authenticated-orcid":false,"given":"Jeffrey C.","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5547-3268","authenticated-orcid":false,"given":"Carol","family":"Hitchon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4065-4151","authenticated-orcid":false,"given":"Diane","family":"Lacaille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5526-663X","authenticated-orcid":false,"given":"J. Antonio","family":"Avi\u00f1a-Zubieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3391-578X","authenticated-orcid":false,"given":"Lawrence W.","family":"Svenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9515-2802","authenticated-orcid":false,"given":"Sasha","family":"Bernatsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2262","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"key":"2022102911151075000_49.5.531.1","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2665-9913(21)00247-2","article-title":"COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses","volume":"3","author":"Fagni","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2022102911151075000_49.5.531.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218946"},{"key":"2022102911151075000_49.5.531.3","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00024-8"},{"key":"2022102911151075000_49.5.531.4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210288"},{"key":"2022102911151075000_49.5.531.5","first-page":"e60","article-title":"American College of Rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2022102911151075000_49.5.531.6","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-324000"},{"key":"2022102911151075000_49.5.531.7","doi-asserted-by":"crossref","first-page":"6454","DOI":"10.1016\/j.vaccine.2021.09.057","article-title":"Characteristics associated with COVID-19 vaccine hesitancy: a nationwide survey of 1000 patients with immune-mediated inflammatory diseases","volume":"39","author":"Vieira Rezende","year":"2021","journal-title":"Vaccine"},{"key":"2022102911151075000_49.5.531.8","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1016\/S2665-9913(21)00039-4","article-title":"Vaccination against COVID-19: expectations and concerns of patients with autoimmune and rheumatic diseases","volume":"3","author":"Felten","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2022102911151075000_49.5.531.9","unstructured":"World Health Organization . Monitoring COVID-19 vaccination: considerations for the collection and use of vaccination data. [Internet. Accessed December 21, 2021.] Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/339993\/WHO-2019-nCoV-vaccination-monitoring-2021.1-eng.pdf"},{"key":"2022102911151075000_49.5.531.10","unstructured":"Ontario Minisitry of Finance . 2016 census highlights: factsheet 9. Ethnic origin and visible minorities. [Internet. Accessed December 21, 2021.] Available from: https:\/\/www.Fin.Gov.On.Ca\/en\/economy\/demographics\/census\/cenhi16-9.html"},{"key":"2022102911151075000_49.5.531.11","unstructured":"Ontario Ministry of Health . Ontario\u2019s three-phased vaccination plan. 2021 [Internet. Accessed December 21, 2021.] Available from: https:\/\/covid-19.ontario.ca\/ontarios-covid-19-vaccination-plan#our-three-phased-vaccination-plan"},{"key":"2022102911151075000_49.5.531.12","unstructured":"Government of Canada . Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada in the context of limited vaccine supply [2021-04-07]. [Internet. Accessed December 21, 2021.] Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html"},{"key":"2022102911151075000_49.5.531.13","unstructured":"Government of Canada . NACI rapid response: extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada [2021-03-03]. [Internet. Accessed December 21, 2021.] Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html"},{"key":"2022102911151075000_49.5.531.14","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190659"},{"key":"2022102911151075000_49.5.531.15","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1002\/acr.22031","article-title":"Accuracy of Canadian health administrative databases in identifying patients with rheumatoid arthritis: a validation study using the medical records of rheumatologists","volume":"65","author":"Widdifield","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2022102911151075000_49.5.531.16","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.jclinepi.2014.02.019","article-title":"Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada","volume":"67","author":"Benchimol","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"2022102911151075000_49.5.531.17","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000103"},{"key":"2022102911151075000_49.5.531.18","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2470"},{"key":"2022102911151075000_49.5.531.19","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/acr.23743","article-title":"Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: a population-based study","volume":"71","author":"Eder","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2022102911151075000_49.5.531.20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.12927\/hcq.2015.24439","article-title":"Rheumatoid arthritis surveillance in Ontario: monitoring the burden, quality of care and patient outcomes through linkage of administrative health data","volume":"18","author":"Widdifield","year":"2015","journal-title":"Healthc Q"},{"key":"2022102911151075000_49.5.531.21","unstructured":"WHO . Ten threats to global health in 2019. [Internet. Accessed Oct 3, 2021.] Available from: https:\/\/www.who.int\/news-room\/spotlight\/ten-threats-to-global-health-in-2019"},{"key":"2022102911151075000_49.5.531.22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001814"},{"key":"2022102911151075000_49.5.531.23","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0140-6736(20)31558-0","article-title":"Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study","volume":"396","author":"de Figueiredo","year":"2020","journal-title":"Lancet"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.211148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T21:48:35Z","timestamp":1700084915000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.211148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,1]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.3899\/jrheum.211148"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.211148","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"type":"print","value":"0315-162X"},{"type":"electronic","value":"1499-2752"}],"subject":[],"published":{"date-parts":[[2022,1,15]]}}}